OBJECTIVE Pioglitazone, an antihyperglycemic drug, increases plasma high-density lipoprotein (HDL)-cholesterol in patients with type 2 diabetes. The mechanisms by which pioglitazone regulate HDL levels are not clear. This study examined the effect of pioglitazone on hepatocyte apolipoprotein AI (apoA-I) and apoA-II production and HDL-protein/cholesterol ester uptake. METHODS AND RESULTS In hu...

background: thiazolidinediones (tzds) improves insulin sensitivity by activating the peroxisome proliferator-activated receptor γ (ppar-g). we aimed to study any association between variation in bone biochemical markers and single nucleotide polymorphism (snp) in ppar- γ (pro12ala) and investigate if these genetic variants affect bone turnover markers in iranian diabetic population before and a...

AIM To evaluate the impact of pioglitazone pharmacotherapy in median nerve electrophysiology in the carpal tunnel among type 2 diabetes patients. METHODS The study was executed in patients with type 2 diabetes, treated with oral drugs, categorized under pioglitazone or non-pioglitazone group (14 in each group), and who received electrophysiological evaluation by nerve conduction velocity at b...

AIMS To compare the efficacy, safety and tolerability of linagliptin or placebo administered for 24 weeks in combination with pioglitazone in patients with type 2 diabetes mellitus (T2DM) exhibiting insufficient glycaemic control (HbA1c 7.5-11.0%). METHODS Patients were randomized to receive the initial combination of 30 mg pioglitazone plus 5 mg linagliptin (n = 259) or pioglitazone plus pla...

BACKGROUND Type 2 diabetes is known to be associated with elevated cardiovascular mortality. Pioglitazone improves blood pressure (BP) and pulse wave velocity (PWV), which is an arterial stiffness parameter. Arterial stiffness is closely associated with cardiovascular disease. However, PWV is correlated with BP. The cardio-ankle vascular index (CAVI) reflects arterial stiffness independent of B...

Pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, is indicated for the treatment of type 2 diabetes. Pioglitazone undergoes hepatic metabolism by cytochrome P450 2C8 (CYP2C8) and interindividual variability exists in pioglitazone disposition and response. In previous analyses, it has been shown that the CYP2C8*3 polymorphism significantly impacts pioglitazone pharmacokinetic...

OBJECTIVE In this post hoc analysis, we examined insulin requirements and regimens, glycemic control, cardiovascular outcomes, and safety in the patients treated with insulin at baseline in the Prospective Pioglitazone Clinical Trial in Macrovascular Events study. DESIGN The Prospective Pioglitazone Clinical Trial in Macrovascular Events study was a double-blind, placebo-controlled outcome st...

Background and Aims: Diabetes mellitus causes testicular damage by increasing oxidative stress and inflammation. In the present study, modulation of oxidative stress by pioglitazone, a synthetic ligand of peroxisome proliferator-activated receptor-γ, was examined in testis of streptozotocin-induced diabetic rats. Materials and Methods: Diabetes was induced by a single dose of streptozot...

Objective(s): Pioglitazone (Actos) is one of the most controversial recent oral antidiabetic drugs. It was originally authorized in the European Union in 2000, and approved as an oral monotherapy for overweight second type of diabetic patients in 2002. It belongs to the thiazolidinedione group which some of its members have been withdrawn from the market due to the hepatotoxicity or cardiotoxic...

Pioglitazone is an oral hypoglycemic drug, used for the treatment of type 2 diabetes. The main objectives this study were to improve aqueous solubility by preparing its solid dispersion fusion method using various carriers that will absorption and subsequent bioavailability. prepared tablets (TF1-TF5) evaluated parameters i.e.shape size, weight variation, hardness, friability, disintegration ti...